PPARalpha activators may play role for the regression of ventricular hypertrophy in hypertensive and hyperlipidemic patients.
Erol
Adnan
A
D002986:Clinical Trials as Topic; D019317:Evidence-Based Medicine; D011345:Fenofibrate / Q000008:administration & dosage*; D006801:Humans; D006949:Hyperlipidemias / Q000150:complications / Q000188:drug therapy / Q000378:metabolism*; D006973:Hypertension / Q000150:complications / Q000188:drug therapy / Q000378:metabolism*; D017379:Hypertrophy, Left Ventricular / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism*; D000960:Hypolipidemic Agents / Q000008:administration & dosage; D008955:Models, Cardiovascular; D047493:PPAR alpha / Q000819:agonists* / Q000378:metabolism*; D016896:Treatment Outcome
D000960:Hypolipidemic Agents; D047493:PPAR alpha; D011345:Fenofibrate